Olezarsen Sodium Patent Expiration
Olezarsen Sodium was first introduced by Ionis Pharmaceuticals Inc
Olezarsen Sodium Patents
Given below is the list of patents protecting Olezarsen Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tryngolza (autoinjector) | US9127276 | Conjugated antisense compounds and their use | May 01, 2034 | Ionis Pharms Inc |
| Tryngolza (autoinjector) | US9163239 | Compositions and methods for modulating apolipoprotein C-III expression | May 01, 2034 | Ionis Pharms Inc |
| Tryngolza (autoinjector) | US9181549 | Conjugated antisense compounds and their use | May 01, 2034 | Ionis Pharms Inc |
| Tryngolza (autoinjector) | US9593333 | Modulation of apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations | Feb 14, 2034 | Ionis Pharms Inc |
| Tryngolza (autoinjector) | US9157082 | Modulation of apolipoprotein CIII (ApoCIII) expression | Apr 27, 2032 | Ionis Pharms Inc |
Olezarsen Sodium's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List